Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Lixisenatide on Post-prandial Lipid Profile in Obese Type 2 Diabetic Patients
2014-002263-15Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of lixisenatide in type 2 diabetes mellitus (T2DM), obesity and postprandial dyslipidemia (PPD), sponsored by Sanofi. Primary endpoint: Effect of lixisenatide on plasma triglyceride changes after 10 weeks of treatment (AUC0-480 min). Started Jun 2014; status: terminated.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesitypostprandial dyslipidemia (PPD)
Beyond the preview
Go deeper on 2014-002263-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002263-15.